Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. "Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe," said Stefan König, CEO of Merz Therapeutics. Merz Therapeutics is headquartered in Frankfurt am Main, Germany, and is active in more than 80 countries. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company with a 118-year legacy.